HUP0400323A2 - Tyrosine kinase inhibitors and pharmaceutical compositions containing them - Google Patents

Tyrosine kinase inhibitors and pharmaceutical compositions containing them

Info

Publication number
HUP0400323A2
HUP0400323A2 HU0400323A HUP0400323A HUP0400323A2 HU P0400323 A2 HUP0400323 A2 HU P0400323A2 HU 0400323 A HU0400323 A HU 0400323A HU P0400323 A HUP0400323 A HU P0400323A HU P0400323 A2 HUP0400323 A2 HU P0400323A2
Authority
HU
Hungary
Prior art keywords
alkyl
heteroaryl
aryl
group
nr60r61
Prior art date
Application number
HU0400323A
Other languages
Hungarian (hu)
Inventor
Mark D. Wittman
Neelakantan Balasubramanian
Upender Velaparthi
Kurt Zimmermann
Mark G. Saulnier
Peiying Liu
Xiaopeng Sang
David B. Frennesson
Karen M. Stoffan
James G. Tarrant
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HUP0400323A2 publication Critical patent/HUP0400323A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

A találmány általános képletű vegyületekre - amelyek képletében Xnitrogén-, szénatom, alkilcsoport vagy kémiai kötés; Y oxigén- vagykénatom; W nitrogén-, szén-, oxigén- vagy kénatom, azzal amegkötéssel, hogy ha W oxigén- vagy kénatom, akkor R9 nincs jelen; R1.R2, R3, R4, R5, R6, R7, R8 és R9 hidrogén-, halogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, heterocikloalkil-, amino-, OR60,nitro-, hidroxi-, -SR60, -NR60R61, ciano-, -CO2R60, -CONR60R61, -CO2-NR60R61, -NR62CONR60R61, -NR60SO2R61, -SO2NR60R61, -C(NR62)-NR60R61,aril-, heteroaril-, -(CH2)nOR60, -(CH2)nNR60R61, -(CH2)nSR60, -(CH2)n-aril, -(CH2)n-heteroaril, -(CH2)n-heterocikloalkil, -NH-Z-aril és -NH-Z-heteroaril csoport; ahol n értéke 1, 2 vagy 3; és Z adott esetbenszubsztituált alkilén-, alkenilén- vagy alkiniléncsoport, amely adottesetben egy vagy több CO, CNOH, CNOR60, CNNR60, CNNCOR60 és/vagyCNNSO2R60 csoportot tartalmaz; R60, R61 és R62 hidrogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, cikloalkil-alkil-, hidroxi-, alkoxi-,aril-, heteroaril-, heteroaril-alkil-csoport, -alkil-R25 csoport; R25hidrogén-, halogénatom, alkenil-, hidroxi-, merkapto-, alkoxi-, alkil-tio-, amino-, alkil-amino-, dialkil-amino-, aril-, heteroaril-,ciano-, szulfinil-, szulfonilcsoport, -NR30COOR31, -NR30C(O)R31, -NR30SO2R31, -C(O)NR30R31, heteroaril vagy heterocikloalkil-csoport;valamint R30, R31 hidrogénatom, alkil-, cikloalkil-, -alkil-R25-csoport - és enantiomereikre, diasztereomereikre, gyógyszerészetilegelfogadható sóikra, hidrátjaikra, prodrugjaikra és szolvátjaikra,ezeket tartalmazó, tirozin-kináz enzimekkel kapcsolatos állapotok, rákés proliferatív betegségek kezelésére használhatógyógyszerkészítményekre vonatkozik.The invention applies to compounds of the general formula - whose formula contains a nitrogen, carbon atom, alkyl group or chemical bond; Y is an oxygen or sulfur atom; W is nitrogen, carbon, oxygen or sulfur, with the proviso that if W is oxygen or sulfur, then R9 is not present; R1.R2, R3, R4, R5, R6, R7, R8 and R9 are hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, amino, OR60, nitro, hydroxy, -SR60 , -NR60R61, cyano-, -CO2R60, -CONR60R61, -CO2-NR60R61, -NR62CONR60R61, -NR60SO2R61, -SO2NR60R61, -C(NR62)-NR60R61,aryl-, heteroaryl-, -(CH2)nOR60, -(CH2 )nNR60R61, -(CH2)nSR60, -(CH2)n-aryl, -(CH2)n-heteroaryl, -(CH2)n-heterocycloalkyl, -NH-Z-aryl and -NH-Z-heteroaryl; where n is 1, 2 or 3; and Z is an optionally substituted alkylene, alkenylene or alkynylene group, optionally containing one or more CO, CNOH, CNOR60, CNNR60, CNNCOR60 and/or CNNSO2R60 groups; R60, R61 and R62 are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, -alkyl-R25; - NR30COOR31, -NR30C(O)R31, -NR30SO2R31, -C(O)NR30R31, heteroaryl or heterocycloalkyl group; as well as R30, R31 hydrogen atom, alkyl-, cycloalkyl-, -alkyl-R25 group - and their enantiomers, diastereomers, pharmaceutically acceptable applies to their salts, hydrates, prodrugs and solvates, medicinal preparations containing them for the treatment of conditions related to tyrosine kinase enzymes, cancer and proliferative diseases.

HU0400323A 2001-03-28 2002-03-26 Tyrosine kinase inhibitors and pharmaceutical compositions containing them HUP0400323A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (en) 2001-03-28 2002-03-26 Novel tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
HUP0400323A2 true HUP0400323A2 (en) 2005-11-28

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400323A HUP0400323A2 (en) 2001-03-28 2002-03-26 Tyrosine kinase inhibitors and pharmaceutical compositions containing them

Country Status (25)

Country Link
EP (1) EP1381598A4 (en)
JP (1) JP2004534010A (en)
KR (1) KR20030083016A (en)
CN (1) CN1514833A (en)
AR (1) AR035804A1 (en)
BG (1) BG108206A (en)
BR (1) BR0208373A (en)
CA (1) CA2442428A1 (en)
CZ (1) CZ20032615A3 (en)
EE (1) EE200300475A (en)
GE (1) GEP20053660B (en)
HR (1) HRP20030844A2 (en)
HU (1) HUP0400323A2 (en)
IL (1) IL158041A0 (en)
IS (1) IS6968A (en)
MX (1) MXPA03008690A (en)
NO (1) NO20034308L (en)
PE (1) PE20021015A1 (en)
PL (1) PL373300A1 (en)
RU (1) RU2003131693A (en)
SK (1) SK12002003A3 (en)
UY (1) UY27234A1 (en)
WO (1) WO2002079192A1 (en)
YU (1) YU84603A (en)
ZA (1) ZA200307466B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
AU2003218236B2 (en) 2002-03-01 2007-12-06 Bristol-Myers Squibb Company Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors
US6921821B2 (en) * 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US7361691B2 (en) * 2002-12-02 2008-04-22 Arqule, Inc. Method of treating cancers using β-lapachone or analogs or derivatives thereof
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
WO2004069160A2 (en) * 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (en) * 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
CN102924458B (en) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
RU2423351C2 (en) * 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Pyrid-2-ones applicable as protein kinase inhibitors of tec family for treating inflammatory, proliferative and immunologically mediated diseases
WO2006130657A2 (en) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Stereoselective reduction process for the preparation of pyrrolotriazine compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007019345A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Imidazopyridine derivatives as sirtuin modulating agents
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1919891B1 (en) 2005-08-29 2012-03-07 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
AU2006285145A1 (en) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-.receptor tyrosine kinases
EP1919906B1 (en) 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases
WO2007026720A1 (en) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Ring-fused pyrazole derivative
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (en) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. Optically active 2-amino-1-(4-fluorophenyl)ethanol
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (en) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
WO2008025526A1 (en) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Indole derivatives, their manufacture and use as pharmaceutical agents
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
CL2008001822A1 (en) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compounds derived from thiazolo [5,4-b] pyridine; pharmaceutical composition comprising said compounds; and use of the compound in the treatment of insulin resistance, metabolic syndrome, diabetes, among others.
CA2690064A1 (en) 2007-06-25 2008-12-31 Guy Georges Benzimidazole amido derivatives as kinase inhibitors
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
WO2009093012A1 (en) 2008-01-22 2009-07-30 Vernalis (R & D) Ltd Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity
JP2011520970A (en) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド Substituted imidazopyrazines and imidazotriazines
UA104447C2 (en) 2008-12-19 2014-02-10 Сіртріз Фармасьютікалз, Інк. Thiazolopyridine sirtuin modulating compounds
DE102010001064A1 (en) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
ES2453097T3 (en) * 2009-05-27 2014-04-04 Abbvie Inc. Pyrimidine Kinase Activity Inhibitors
WO2011053779A2 (en) 2009-10-30 2011-05-05 Bristol-Myers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
HUE033209T2 (en) * 2010-10-06 2017-11-28 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP5789888B2 (en) * 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzimidazole inhibitors of leukotriene formation
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
DK3010503T3 (en) 2013-06-21 2020-05-25 Zenith Epigenetics Ltd New bicyclic bromodomain inhibitors
CA2915561C (en) * 2013-06-21 2020-09-22 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
JP6542212B2 (en) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel quinazolinones as bromodomain inhibitors
CN103936719A (en) * 2014-05-14 2014-07-23 中国药科大学 Preparation method and application of benzimidazoles derivatives
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
CA2966298A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
CA2982664A1 (en) * 2015-04-16 2016-10-20 Merck Patent Gmbh 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
EP3914698A1 (en) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
CN117069696A (en) * 2023-08-17 2023-11-17 中国药科大学 Double-target small molecule inhibitor and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
CZ302775B6 (en) * 1999-06-23 2011-11-02 Sanofi - Aventis Deutschland GmbH Substituted benzimidazoles
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
PE20021015A1 (en) 2002-11-10
RU2003131693A (en) 2005-05-10
PL373300A1 (en) 2005-08-22
YU84603A (en) 2006-03-03
KR20030083016A (en) 2003-10-23
JP2004534010A (en) 2004-11-11
CA2442428A1 (en) 2002-10-10
EP1381598A1 (en) 2004-01-21
GEP20053660B (en) 2005-11-10
IL158041A0 (en) 2004-03-28
MXPA03008690A (en) 2003-12-12
AR035804A1 (en) 2004-07-14
SK12002003A3 (en) 2004-10-05
ZA200307466B (en) 2005-01-13
EE200300475A (en) 2004-02-16
BG108206A (en) 2004-11-30
WO2002079192A1 (en) 2002-10-10
BR0208373A (en) 2005-02-22
CZ20032615A3 (en) 2004-03-17
CN1514833A (en) 2004-07-21
NO20034308L (en) 2003-11-26
NO20034308D0 (en) 2003-09-26
IS6968A (en) 2003-09-26
EP1381598A4 (en) 2008-03-19
UY27234A1 (en) 2002-10-31
HRP20030844A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
HUP0400323A2 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
CY1107915T1 (en) TRYCYCLIC COPYRIPES OR SPYROPYRROLIDES
HUP0401783A2 (en) 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands, their use and pharmaceutical compositions containing them
SE0104140D0 (en) Novel Compounds
CY1108894T1 (en) NEW PRODUCERS OF VENZIMIDAZOL
HUP0303756A2 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands and process for their preparation and pharmaceutical compositions containing them
DE60226912D1 (en) Quinoline and chianzoline derivatives for the treatment of tumors
HUP0402225A2 (en) Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them
PE20040155A1 (en) AMINOINAZOLE DERIVATIVES, PREPARATION PROCEDURE AND INTERMEDIATES OF THIS PROCEDURE AS A DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HUP0300838A2 (en) Novel heteroaryl derivatives, process for their preparation and the use thereof as pharmaceuticals
HUP0500573A2 (en) Triphenyl-ethylene derivatives as selective estrogen receptor modulators and pharmaceutical compositions containing the same
HUP0401009A2 (en) 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them
CY1107677T1 (en) Derivatives of 1- [INDOL-3-YL) CARBONYL] PIPERAZINE
ATE307810T1 (en) IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS
NO20054361D0 (en) Benzenesylphonamide derivatives, methods of preparation and use thereof for treating pain
AP1816A (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists.
ATE501128T1 (en) 1,2,3-TRIAZOLAMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION
HUP0203054A2 (en) Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use
HUP0201356A2 (en) Use of estrogen agonists/antagonists for producing pharmaceutical composition useful for treating depression or preventing deterioration of cognitive function
ATE498600T1 (en) INDENE DERIVATIVES AS PHARMACEUTICALS
HUP0400341A2 (en) Cyano-substituted dihydropyrimidine compounds and their use
DE60208694D1 (en) PIPERIDINYLMORPHOLINYL DERIVATIVES AS CHEMOKIN RECEPTOR ACTIVITY MODULATORS
DE60237512D1 (en) N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
HUP0303186A2 (en) 4-aminobenzopyran derivatives
DE60314381D1 (en) BENZYLIMIDAZOLYL SUBSTITUTED 2-CHINOLONE AND CHINAZOLINONE DERIVATIVES FOR USE AS FARNESYL TRANSFERASE INHIBITORS

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees